The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1182
May 10, 2004
View Complete Issue         Table of Contents 2019 
Issue 1182
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Cholesterol Rethink for High-Risk Patients
May 10, 2004 (Issue: 1182)
The recent "PROVE IT" trial in patients with coronary heart disease showed clinical benefits associated with reducing LDL cholesterol concentrations lower than the 100 mg/dL (2.59 mmol/L) or less that had been considered optimal.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1182
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.